I-Mab

168 articles about I-Mab

• I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

  3/30/2021

  I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for initiating phase 1 trial for bispecific antibody TJ-CD4B/ABL111

• I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

  3/29/2021

  18 significant clinical milestones achieved since the Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets expected in 2021 New drug application (NDA) submission for felzartamab (TJ202) CD38 antibody for treatment of relapsed or refractory multiple myeloma on track for 2021

• I-Mab to Host 2021 R&D Day

  3/24/2021

  I-Mab to host Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts

• I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

  3/11/2021

  I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced that a poster highlighting the mechanistic differentiation and preclinical research for uliledlimab (also known as TJD5) will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting

• I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

  3/10/2021

  - New Initiative is part of I-Mab’s long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules - I-Mab continues to focus on delivering on key clinical programs while building pipeline of next generation assets

• I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

  3/3/2021

  I-Mab has Conference Call Scheduled for March 29 at 8:00 a.m. ET with Pre-Registration Required

• I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

  2/25/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 pivotal trial (TALLER) for eftansomatropin alfa (also known as TJ101) as a weekly treatment for pediatric growth hormone deficiency (PGHD) in China

• I-Mab Announces Upcoming Participation at March Conferences

  2/24/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March.

• I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

  2/10/2021

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics

• Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced

  2/9/2021

  A registered follow-on public offering by certain pre-IPO shareholders of 3,283,950 American depositary shares of I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, has priced on February 8, 2021 at a public offering price of US$54.0 per ADS.

• Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab

  2/5/2021

  I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced the commencement of a proposed registered underwritten public offering by certain pre-IPO shareholders of American depositary shares, each ten ADSs representing twenty-three ordinary shares of the Company.

• I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China

  2/4/2021

  I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinical trial ( NCT04600817 ) of TJ107 (efineptakin alpha), a novel long-acting reco

• I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

  1/25/2021

  I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States.

• I-Mab Announces Upcoming Participation at January Conferences

  12/23/2020

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in January. Details of the conferences and management presentation are as follows:

• I-Mab Added to Nasdaq Biotechnology Index

  12/14/2020

  - Global biotech index widely followed and tracked by investors and ETFs - IMAB added to the index upon first annual review since IPO - To be effective prior to the U.S. market open on Monday, December 21, 2020   [14-December-2020]   SHANGHAI and GAITHERSBURG, Md. , Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical st

• I-Mab Files Shelf Registration Statement for PIPE Investors

  12/1/2020

  I-Mab filed a registration statement on Form F-1 with the Securities and Exchange Commission by using a "shelf" registration process with respect to 25,123,751 ordinary shares of the Company beneficially owned by certain shareholders, which are parties to the privately negotiated subscription agreements with the Company dated September 3, 2020.

• I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

  12/1/2020

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the strengthening of its Scientific Advisory Board ("SAB") with the appointment of leading international experts Dr. Chen Dong and Dr.

• I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial

  11/13/2020

  I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that it will hold a call with investors on Friday, November 13 at 8:20 a.m. ET to provide deep dive analysis of preliminary clinical efficacy results of its U.S.

• I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting

  11/9/2020

  - Initial monotherapy results demonstrate differentiated safety and PK profile and efficacy signal of lemzoparlimab for the treatment of relapsed/refractory malignancy - I-Mab to host call for investors on November 9 at 8:30am ET

• I-Mab Announces Upcoming Participation at November Conferences

  10/28/2020

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follow